Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company focused on mRNA medicines, with multiple approved vaccines and a broad clinical pipeline. The MRNA news page on Stock Titan aggregates company announcements, investor updates and regulatory developments so readers can follow how Moderna’s strategy and pipeline progress translate into real-world events.
Investors and observers can use this feed to track commercial updates on products such as Spikevax, mRESVIA and mNEXSPIKE, along with developments in late-stage respiratory programs like the seasonal influenza vaccine mRNA-1010, the flu/COVID combination vaccine mRNA-1083 and the Norovirus vaccine candidate mRNA-1403. News items often cover regulatory submissions and opinions from agencies including the U.S. Food and Drug Administration, the European Medicines Agency, Health Canada and others.
The page also surfaces pipeline and clinical trial news in oncology and rare diseases, including updates on mRNA-4157 (intismeran autogene), mRNA-4359, mRNA-3927 for propionic acidemia and mRNA-3705 for methylmalonic acidemia. Announcements related to partnerships, such as CEPI’s funding commitment for the H5 pandemic influenza vaccine candidate mRNA-1018, appear here as well.
In addition, the MRNA news feed includes financial results, guidance and capital structure updates, such as quarterly earnings releases, multi-year financial frameworks and information on facilities like the $1.5 billion credit agreement. Corporate items, including participation in healthcare conferences, Analyst Day presentations and shareholder meeting outcomes, are also reflected.
By reviewing this consolidated news stream, readers can see how Moderna’s respiratory vaccine franchise, oncology and rare disease programs, manufacturing expansion and financing decisions evolve over time, all based on the company’s own disclosures and related announcements.
Moderna, Inc. (Nasdaq: MRNA) reported its first profitable quarter, aiding over 100 million individuals with its COVID-19 vaccine. The company raised its supply forecast for 2021 to 800 million doses, aiming for 1 billion. Promising data from recent clinical trials indicate a 96% vaccine efficacy in adolescents and strong responses to variant booster doses. Additionally, Moderna is expanding its pipeline with 24 mRNA programs, including candidates for RSV and CMV vaccines. The company is set to initiate its Biologics License Application for its COVID-19 vaccine this month.
Moderna (Nasdaq: MRNA) announced a new supply agreement with the Swiss Federal Government to deliver 7 million doses of its booster vaccine in 2022, with an option for an additional 7 million doses for late 2022 or early 2023, contingent on regulatory approval. This follows prior agreements totaling 13.5 million doses. Data from a Phase 2 study indicates that booster doses increased neutralizing antibody responses against SARS-CoV-2 variants. Safety profiles for the booster were comparable to prior doses. Moderna continues to adapt its vaccine to combat emerging variants.
Moderna (MRNA) announced promising data from its Phase 2 study, demonstrating that a 50 µg booster dose of its mRNA-1273.351 vaccine significantly increases neutralizing antibody titers against SARS-CoV-2 and its variants, B.1.351 and P.1. The study found a boost in titers for all participants following the booster. mRNA-1273.351 outperformed mRNA-1273 against B.1.351, with a geometric mean titer of 1400 compared to 864. Safety profiles were comparable to previous doses, with mild to moderate adverse effects. Future data on the multivalent booster mRNA-1273.211 is anticipated.
Moderna, Inc. (Nasdaq: MRNA) has announced an expansion of the Moderna Technology Center in Norwood, MA, set to more than double its space from 300,000 to 650,000 square feet. This growth will enhance production capabilities, particularly for the COVID-19 vaccine, expecting a 50% increase in output by early 2022. The expansion supports plans for global capacity reaching up to 3 billion doses in 2022, and focuses on technical development and preclinical production. The facility integrates advanced technologies and adheres to environmental standards.
Moderna, Inc. (Nasdaq: MRNA) has signed an agreement with Gavi, the Vaccine Alliance to supply up to 500 million doses of its COVID-19 vaccine, including an initial 34 million doses in Q4 2021. This deal supports low- and middle-income countries via the COVAX Facility, furthering Moderna’s commitment to equitable vaccine access. Additionally, the World Health Organization has granted Emergency Use Listing for Moderna's vaccine, enhancing its global reach. The agreement highlights Moderna's pivotal role in combating the COVID-19 pandemic.
Moderna, Inc. (Nasdaq: MRNA) announced the World Health Organization's (WHO) issuance of an Emergency Use Listing (EUL) for its COVID-19 vaccine, applicable to individuals 18 and older. This listing facilitates regulatory approvals for countries and enables UNICEF to procure the vaccine. Based on extensive clinical study data, the EUL promotes faster access to vaccines globally, particularly in lower-income regions. CEO Stéphane Bancel emphasized the significance of this step in combating the COVID-19 pandemic, ensuring equitable vaccine access worldwide.
Moderna (Nasdaq: MRNA) has announced new funding commitments to enhance manufacturing capabilities, aiming to increase its global COVID-19 vaccine supply to up to 3 billion doses in 2022. This capacity boost involves doubling production at Lonza in Switzerland and over doubling at Rovi in Spain. The company is also in advanced negotiations for further agreements. Moderna expects heightened demand for vaccines due to the emergence of variants and waning immunity. The company aims to enhance its vaccine's shelf life and is actively developing new formulations.
DNA Script announced a partnership with Moderna (MRNA) to develop a prototype for mobile vaccine and therapeutic manufacturing under DARPA's Nucleic Acids On-Demand World-Wide Program. This collaboration will utilize DNA Script's enzymatic synthesis platform to produce high-fidelity nucleic acids, enhancing Moderna's mRNA technology. DNA Script will receive up to $5 million in grant funding from DARPA. The initiative aims to create mobile units for rapid production of mRNA vaccines, potentially offering immediate medical responses to pathogen threats.
Moderna (Nasdaq: MRNA) has signed an agreement with Sanofi (Nasdaq: SNY) for fill/finish sterile manufacturing and packaging of up to 200 million doses of the Moderna COVID-19 Vaccine in the U.S., starting September 2021. This partnership aims to enhance production capacity, with Sanofi utilizing its manufacturing site in Ridgefield, NJ. Juan Andres, Moderna’s Chief Technical Operations and Quality Officer, expressed gratitude to the Department of Health and Human Services and the Biden Administration for facilitating this collaboration, emphasizing its importance for scaling up vaccine supply.
Moderna, Inc. (Nasdaq: MRNA) announced a new supply agreement with Israel for 2022, allowing Israel to purchase doses of Moderna's COVID-19 vaccine and a variant-specific vaccine pending regulatory approval. This follows two previous agreements totaling 10 million doses. CEO Stéphane Bancel emphasized the significance of this agreement as a milestone for 2022 supply and ongoing clinical trials for variant-specific boosters, which have shown promising preclinical efficacy against COVID-19 variants.